

**Table S1. TNM grading and metastasis status of patients at baseline**

<b>TNM grading</b>	<b>n (%)</b>	<b>T0</b>	<b>T1</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T unknown</b>	<b>N0</b>	<b>N1</b>	<b>N unknown</b>
M0	6 (13%)	1	0	1	3	1	0	3	3	0
M1	33 (72%)	2	2	8	7	12	2	11	19	3
Unknown	7 (15%)	0	0	0	0	1	6	1	0	6
Total	46	3	2	9	10	14	8	15	22	9

TNM Tumour Node Metastasis

**Table S2. WHO (2010) grading of tumours and Ki67 scores for patients at baseline**

<b>WHO (2010) Tumour Classification</b>	<b>n (%)</b>	<b>Ki 67 Index Score Mean, SD (n)</b>
G1	15 (33%)	1.5, 1.2 (n=13)
G2	24 (52%)	10.4, 8.7 (n=20)
G3	1 (0.02%)	26, 26 (n=1)
unknown	6 (13%)	-

**Table S3. Number of anti-cancer treatments prior to everolimus initiation**

<b>Number of previous treatments</b>	<b>No. of patients</b>	<b>% (n=48)</b>
0	12	25%
1	17	35%
2	6	13%
3	9	19%
4	2	4%
5	2	4%
<b>Total</b>	<b>48</b>	-

**Table S4. Therapies received prior to start of everolimus**

<b>Therapies received PRIOR to start of everolimus</b>	<b>No. of patients</b>	<b>% (n=48)</b>
Proton pump inhibitors	16	33%
Somatostatin and analogs	11	23%
Anilides	9	19%
Biguanides	7	15%
5-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors	6	13%
Natural opium alkaloids	6	13%
Propulsives	5	10%
Salicylic acid and derivatives	4	8%
Sulfonamides, urea derivatives	4	8%
Angiotensin converting enzyme (ACE) inhibitors, plain	3	6%
Alpha-adrenoreceptor antagonists	3	6%
Antipropulsives	3	6%
Beta-lactamase sensitive penicillins	3	6%
Dihydropyridine derivatives	3	6%
Heparin group	3	6%
Opium alkaloids and derivatives	3	6%
Selective serotonin reuptake inhibitors	3	6%
Ophthalmologicals	13	27%
Unspecified herbal and traditional medicine	4	8%

**Table S5. Reasons for discontinuation of everolimus treatment**

<b>Reasons for discontinuation (FAS)</b>	<b>n</b>	<b>%</b>
Patients who discontinued	23	
Reasons for discontinuation		
Adverse event	11	48%
Disease progression	4	17%
Unsatisfactory therapeutic effect	2	9%
Death	1	4%
Lost to follow-up	1	4%
Unknown	4	17%

**Table S6. EORTC QLQ-C30 scores during the first 6 months of treatment with everolimus.** Data presented as: <sup>a</sup>mean (Standard deviation); <sup>b</sup>mean (95% confidence intervals); <sup>c</sup>% change in mean from baseline.

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>EORTC QLQ-C30: Global health status</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	58.0 (20.3)	57.6 (20.9)	56.7 (20.0)	56.0 (19.8)	56.6 (19.2)	56.9 (17.9)
<b>Post-initiation score at Month<sup>a</sup></b>	54.2 (24.9)	56.8 (22.8)	50.9 (19.9)	59.3 (20.5)	53.3 (19.9)	55.0 (18.5)
<b>Absolute change<sup>b</sup></b>	-3.8 (-11.8 to 4.3)	-0.8 (-7.3 to 5.7)	-5.8 (-12.9 to 1.3)	3.2 (-4.7 to 11.2)	-3.3 (-12.8 to 6.2)	-1.9 (-10.9 to 7)
<b>% Change<sup>c</sup></b>	-6.5%	-1.3%	-10.2%	5.8%	-5.8%	-3.4%
<b>EORTC QLQ-C30: Physical functioning</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	75.5 (21.2)	74.1 (23.1)	75.0 (20.4)	74.4 (21.4)	75.2 (20.8)	75.8 (20.3)

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Post-initiation Month score<sup>a</sup></b>	70.6 (23.4)	70.1 (24.2)	65.2 (25.8)	70.4 (25.7)	68.1 (25.0)	72.7 (21.1)
<b>Absolute change<sup>b</sup></b>	<b>-4.8</b> <b>(-9.6 to -0.1)</b>	-4 (-9.3 to 1.3)	<b>-9.8</b> <b>(-16.8 to -2.8)</b>	-4.1 (-10.1 to 1.9)	<b>-7.1</b> <b>(-14.1 to -0.1)</b>	-3.1 (-9.8 to 3.6)
<b>% Change<sup>c</sup></b>	-6.4%	-5.4%	-13.1%	-5.5%	-9.4%	-4.1%
<b>EORTC QLQ-C30: Role functioning</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	64.8 (30.5)	62.8 (31.9)	62.5 (31.0)	62.0 (30.8)	64.6 (32.2)	66.1 (28.9)
<b>Post-initiation Month score<sup>a</sup></b>	61.4 (35.2)	63.6 (30.5)	58.8 (30.7)	63.9 (32.7)	56.6 (27.9)	62.2 (28.0)
<b>Absolute change<sup>b</sup></b>	-3.4 (-13.2 to 6.3)	0.8 (-7.6 to 9.1)	-3.7 (-12.8 to 5.4)	1.9 (-6.7 to 10.4)	-8.1 (-18.2 to 2.1)	-3.9 (-16.1 to 8.3)
<b>% Change<sup>c</sup></b>	-5.3%	1.2%	-5.9%	3.0%	-12.5%	-5.9%
<b>EORTC QLQ-C30: Emotional functioning</b>						

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	72.9 (22.2)	72.9 (22.3)	71.1 (22.9)	70.8 (23.1)	71.2 (23.4)	69.4 (23.9)
<b>Post-initiation Month score<sup>a</sup></b>	70.1 (27.8)	71.7 (23.9)	69.4 (22.9)	68.3 (27.4)	69.2 (26)	66.1 (24)
<b>Absolute change<sup>b</sup></b>	-2.8 (-8.3 to 2.6)	-1.2 (-5.8 to 3.4)	-1.6 (-8 to 4.7)	-2.5 (-10.4 to 5.3)	-2 (-8.8 to 4.7)	-3.3 (-11 to 4.3)
<b>% Change<sup>c</sup></b>	-3.9%	-1.6%	-2.3%	-3.6%	-2.8%	-4.8%
<b>EORTC QLQ-C30: Cognitive functioning</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	81.1 (18.5)	81 (18.8)	80.6 (19.3)	80.6 (19.3)	79.3 (20)	80.6 (19.1)
<b>Post-initiation Month score<sup>a</sup></b>	79.9 (22.6)	79.8 (24)	76.9 (21.6)	77.8 (22.9)	77.3 (23.5)	78.3 (22.4)
<b>Absolute change<sup>b</sup></b>	-1.1 (-6.9 to 4.6)	-1.2 (-7.8 to 5.5)	-3.7 (-10 to 2.6)	-2.8 (-9.2 to 3.6)	-2 (-10.1 to 6)	-2.2 (-10.4 to 5.9)

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>% Change<sup>c</sup></b>	-1.4%	-1.4%	-4.6%	-3.4%	-2.5%	-2.8%
<b>EORTC QLQ-C30: Social functioning</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	67.4 (29)	66.3 (29)	63 (29.6)	63 (29.8)	64.6 (30.3)	65.6 (29)
<b>Post-initiation Month score<sup>a</sup></b>	62.1 (30.6)	65.1 (27.7)	66.2 (31)	69.9 (28.4)	63.1 (29.1)	68.9 (29.3)
<b>Absolute change<sup>b</sup></b>	-5.3 (-15.1 to 4.5)	-1.2 (-9.3 to 7)	3.2 (-6.6 to 13.1)	6.9 (-1.9 to 15.8)	-1.5 (-11.4 to 8.3)	3.3 (-8.4 to 15.1)
<b>% Change<sup>c</sup></b>	-7.9%	-1.8%	5.1%	11.0%	-2.3%	5.1%
<b>EORTC QLQ-C30: Fatigue</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	41.2 (22.6)	42.1 (22.7)	42.9 (22.2)	42.3 (23.1)	43.1 (23.9)	40 (19.9)
<b>Post-initiation Month score<sup>a</sup></b>	47.5 (28.9)	43.4 (27)	46.3 (25.5)	42 (26.4)	44.8 (23)	44.4 (26.7)



	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Absolute change<sup>b</sup></b>	6.3 (-2.8 to 15.4)	1.3 (-6 to 8.6)	3.4 (-5.1 to 11.9)	-0.3 (-8.9 to 8.3)	1.7 (-7.8 to 11.2)	4.4 (-6.8 to 15.7)
<b>% Change<sup>c</sup></b>	15.3%	3.1%	7.9%	-0.7%	3.9%	11.1%
<b>EORTC QLQ-C30: Nausea and vomiting</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	8.3 (15.5)	8.5 (15.6)	9.7 (16.6)	9.3 (16.6)	8.1 (16.7)	8.3 (17.4)
<b>Post-initiation Month score<sup>a</sup></b>	14.8 (20.1)	10.5 (15)	8.8 (15.2)	7.4 (12.9)	7.6 (14.5)	8.3 (12.2)
<b>Absolute change<sup>b</sup></b>	6.4 (-0.9 to 13.8)	1.9 (-3.6 to 7.4)	-0.9 (-6.6 to 4.8)	-1.9 (-7.4 to 3.7)	-0.5 (-5.3 to 4.3)	0 (-5.7 to 5.7)
<b>% Change<sup>c</sup></b>	77.3%	22.7%	-9.5%	-20.0%	-6.3%	0.0%
<b>EORTC QLQ-C30: Pain</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	26.1 (27.2)	26.7 (27.7)	25 (27.2)	24.5 (25.4)	23.2 (25)	27.8 (28.5)

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Post-initiation Month score<sup>a</sup></b>	29.2 (33)	29.8 (29.9)	27.3 (25.6)	20.4 (24.6)	26.3 (25.7)	28.9 (26.6)
<b>Absolute change<sup>b</sup></b>	3 (-6.8 to 12.8)	3.1 (-5.6 to 11.8)	2.3 (-7.2 to 11.9)	-4.2 (-13.8 to 5.5)	3 (-7.6 to 13.6)	1.1 (-11.6 to 13.9)
<b>% Change<sup>c</sup></b>	11.6%	11.6%	9.3%	-17.0%	13.0%	4.0%
<b>EORTC QLQ-C30: Dyspnea</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	15.2 (20.9)	17.1 (24.5)	13.9 (21.6)	14.8 (21.7)	14.1 (22.1)	11.1 (16)
<b>Post-initiation Month score<sup>a</sup></b>	23.5 (25.5)	19.4 (25.4)	25.9 (28.9)	15.7 (24.5)	19.2 (25)	14.4 (18.9)
<b>Absolute change<sup>b</sup></b>	8.3 (0.7 to 15.9)	2.3 (-3.8 to 8.4)	12 (1.9 to 22.2)	0.9 (-6.5 to 8.3)	5.1 (-2.8 to 12.9)	3.3 (-4.2 to 10.9)
<b>% Change<sup>c</sup></b>	55.0%	13.6%	86.7%	6.2%	35.7%	30.0%
<b>EORTC QLQ-C30: Insomnia</b>						

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	37.9 (37.1)	38.8 (37)	36.1 (37.7)	33.3 (34.7)	37.4 (36.1)	35.6 (34.9)
<b>Post-initiation Month score<sup>a</sup></b>	39.4 (36.8)	45 (34)	40.7 (27.7)	27.8 (29.3)	31.3 (31.1)	40 (34.4)
<b>Absolute change<sup>b</sup></b>	1.5 (-8.5 to 11.5)	6.2 (-4.4 to 16.8)	4.6 (-5.9 to 15.1)	-5.6 (-18.3 to 7.2)	-6.1 (-16.1 to 3.9)	4.4 (-11.5 to 20.4)
<b>% Change<sup>c</sup></b>	4.0%	16.0%	12.8%	-16.7%	-16.2%	12.5%
<b>EORTC QLQ-C30: Appetite loss</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	28.8 (31)	29.5 (31)	26.9 (30.7)	29.6 (30.6)	28.3 (30.2)	27.8 (29.1)
<b>Post-initiation Month score<sup>a</sup></b>	31.1 (39)	29.5 (31)	36.1 (31.2)	22.2 (26.4)	28.3 (27.8)	23.3 (26.5)
<b>Absolute change<sup>b</sup></b>	2.3 (-10 to 14.5)	0 (-9.5 to 9.5)	9.3 (-2.4 to 20.9)	-7.4 (-17.5 to 2.7)	0 (-12.9 to 12.9)	-4.4 (-16.6 to 7.7)

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>% Change<sup>c</sup></b>	7.9%	0.0%	34.5%	-25.0%	0.0%	-16.0%
<b>EORTC QLQ-C30: Constipation</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	19.7 (27.2)	20.2 (27.4)	16.7 (24.6)	19.4 (25.7)	22.2 (29.7)	24.4 (28.9)
<b>Post-initiation Month score<sup>a</sup></b>	15.2 (25.4)	17.1 (31.2)	14.8 (24.5)	18.5 (24.5)	13.1 (24.9)	14.4 (27.2)
<b>Absolute change<sup>b</sup></b>	-4.5 (-12.3 to 3.2)	-3.1 (-12 to 5.8)	-1.9 (-9 to 5.3)	-0.9 (-9.2 to 7.4)	-9.1 (-20.3 to 2.1)	-10 (-22.7 to 2.7)
<b>% Change<sup>c</sup></b>	-23.1%	-15.4%	-11.1%	-4.8%	-40.9%	-40.9%
<b>EORTC QLQ-C30: Diarrhea</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	17.4 (28.3)	17.1 (27.6)	19.4 (30.2)	19.4 (30.2)	22.2 (30.8)	21.1 (30.9)
<b>Post-initiation Month score<sup>a</sup></b>	22.7 (32.8)	26.4 (33.8)	25 (33.2)	17.6 (29.3)	28.3 (34.5)	23.3 (29.2)

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Absolute change<sup>b</sup></b>	5.3 (-4.7 to 15.3)	9.3 (-0.8 to 19.4)	5.6 (-5.4 to 16.5)	-1.9 (-11.9 to 8.2)	6.1 (-4.4 to 16.5)	2.2 (-10 to 14.4)
<b>% Change<sup>c</sup></b>	30.4%	54.5%	28.6%	-9.5%	27.3%	10.5%
<b>EORTC QLQ-C30: Financial difficulties</b>						
<b>Number of patients with paired scores</b>	44	43	36	36	33	30
<b>Baseline score<sup>a</sup></b>	17.4 (27.4)	17.1 (26.6)	19.4 (29.1)	20.4 (29)	19.2 (28.9)	18.9 (28.6)
<b>Post-initiation Month score<sup>a</sup></b>	18.2 (30)	12.4 (26.2)	19.4 (32.2)	20.4 (34.1)	20.2 (32.2)	18.9 (29.9)
<b>Absolute change<sup>b</sup></b>	0.8 (-6 to 7.5)	-4.7 (-10.8 to 1.5)	0 (-6.6 to 6.6)	0 (-7.1 to 7.1)	1 (-7.1 to 9.1)	0 (-9.2 to 9.2)
<b>% Change<sup>c</sup></b>	4.3%	-27.3%	0.0%	0.0%	5.3%	0.0%

**Table S7. EORTC QLQ-GI.NET21 scores during the first 6 months of treatment with everolimus.** Data presented as: <sup>a</sup>mean (standard deviation); <sup>b</sup>mean change from baseline (95% confidence intervals); <sup>c</sup>% change in mean from baseline; <sup>d</sup>mean score (95% confidence intervals) – treatment -related symptoms scale only completed by n=17 patients at baseline therefore post-initiation data were not compared with baseline.

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>EORTC QLQ-GI.NET21: Endocrine symptoms</b>						
<b>Number of patients with paired scores</b>	44	43	36	35	33	30
<b>Baseline score<sup>a</sup></b>	13.6 (16.3)	14.0 (16.6)	14.8 (17.6)	15.6 (17.7)	15.2 (18.4)	14.4 (16.3)
<b>Post-initiation score at Month<sup>a</sup></b>	12.9 (17.0)	11.1 (19.8)	12.3 (16.5)	12.4 (17.8)	12.8 (15.5)	12.6 (15.4)
<b>Absolute change<sup>b</sup></b>	-0.8 (-6.3 to 4.8)	-2.8 (-8.8 to 3.1)	-2.5 (-8.1 to 3.2)	-3.2 (-10.4 to 4)	-2.4 (-8.9 to 4.2)	-1.9 (-9 to 5.3)
<b>% Change<sup>c</sup></b>	-5.6%	-20.4%	-16.7%	-20.4%	-15.6%	-12.8%
<b>EORTC QLQ-GI.NET21: Gastrointestinal symptoms</b>						
<b>Number of patients with paired scores</b>	44	43	36	35	33	30

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Baseline score<sup>a</sup></b>	23.9 (19.8)	23.9 (20.1)	24.4 (20.2)	25.7 (20.7)	26.1 (20.0)	25.8 (18.4)
<b>Post-initiation Month score<sup>a</sup></b>	25.8 (24.6)	23.3 (20.1)	20.2 (14.2)	19.0 (15.0)	20.8 (17.4)	21.8 (17.9)
<b>Absolute change<sup>b</sup></b>	1.8 (-5.6 to 9.2)	-0.6 (-6.2 to 5)	-4.3 (-10.2 to 1.7)	-6.7 (-13 to -0.3)	-5.3 (-11.4 to 0.9)	-4.0 (-12 to 4)
<b>% Change<sup>c</sup></b>	7.6%	-2.6%	-17.4%	-25.9%	-20.2%	-15.5%
<b>EORTC QLQ-GI.NET21: Social function</b>						
<b>Number of patients with paired scores</b>	44	43	36	35	33	30
<b>Baseline score<sup>a</sup></b>	42.2 (25.9)	42.4 (25.5)	44.1 (26.2)	46.0 (25.3)	44.1 (24.6)	44.8 (24.0)
<b>Post-initiation Month score<sup>a</sup></b>	41.2 (23.1)	39.0 (23.8)	42.6 (24.4)	35.9 (26.4)	39.1 (24.2)	34.4 (22.9)
<b>Absolute change<sup>b</sup></b>	-1 (-7.2 to 5.2)	-3.4 (-10 to 3.3)	-1.5 (-9.4 to 6.4)	-10.2 (-17.1 to -3.2)	-5.1 (-13.1 to 3)	-10.4 (-18.4 to -2.4)
<b>% Change<sup>c</sup></b>	-2.4%	-7.9%	-3.5%	-22.1%	-11.5%	-23.1%
<b>EORTC QLQ-GI.NET21: Disease related worries</b>						

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Number of patients with paired scores</b>	44	43	36	35	33	30
<b>Baseline score<sup>a</sup></b>	49.4 (29.3)	47.0 (28.9)	51.1 (28.0)	51.9 (28.5)	49.2 (27.1)	50.9 (28.3)
<b>Post-initiation Month score<sup>a</sup></b>	37.4 (22.0)	38.9 (26.3)	44.8 (23.5)	45.2 (27.3)	42.1 (27.4)	43.7 (27.0)
<b>Absolute change<sup>b</sup></b>	<b>-12</b> (-18.6 to -5.4)	<b>-8.1</b> (-14.7 to -1.6)	-6.3 (-12.6 to 0)	-6.7 (-14.8 to 1.5)	-7.1 (-14.5 to 0.4)	-7.2 (-16.2 to 1.8)
<b>% Change<sup>c</sup></b>	-24.3%	-17.3%	-12.4%	-12.8%	-14.4%	-14.2%
<b>EORTC QLQ-GI.NET21: Muscle/bone pain symptom</b>						
<b>Number of patients with paired scores</b>	44	43	36	35	33	30
<b>Baseline score<sup>a</sup></b>	33.3 (26.1)	32.6 (26.7)	35.2 (26.4)	33.3 (25.6)	35.4 (24.9)	33.3 (24.8)
<b>Post-initiation Month score<sup>a</sup></b>	25.0 (25.0)	24.8 (29.2)	35.2 (26.4)	30.5 (27.3)	32.3 (27.0)	30.0 (29.5)
<b>Absolute change<sup>b</sup></b>	-8.3 (-16.8 to 0.2)	-7.8 (-18.9 to 3.4)	0.0 (-12.1 to 12.1)	-2.9 (-13.4 to 7.7)	-3.0 (-14.2 to 8.2)	-3.3 (-15.7 to 9)



	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>% Change<sup>c</sup></b>	-25.0%	-23.8%	0.0%	-8.6%	-8.6%	-10.0%
<b>EORTC QLQ-GI.NET21: Information/communication function</b>						
<b>Number of patients with paired scores</b>	44	43	36	35	33	30
<b>Baseline score<sup>a</sup></b>	2.3 (8.4)	2.3 (8.6)	01.9 (7.7)	1.9 (7.9)	1.0 (5.8)	1.1 (6.1)
<b>Post-initiation Month score<sup>a</sup></b>	2.3 (14.9)	3.1 (16.0)	04.6 (14.1)	1.9 (7.9)	4.0 (13.8)	1.1 (6.1)
<b>Absolute change<sup>b</sup></b>	0.0 (-5.4 to 5.4)	0.8 (-4.9 to 6.5)	2.8 (-2.9 to 8.4)	0.0 (-2.8 to 2.8)	3.0 (-2.4 to 8.4)	0.0 (-3.3 to 3.3)
<b>% Change</b>	0.0%	33.3%	150.0%	0.0%	300.0%	0.0%
<b>EORTC QLQ-GI.NET21: Body image</b>						
<b>Number of patients with paired scores</b>	44	43	36	35	33	30
<b>Baseline score<sup>a</sup></b>	21.2 (31.2)	21.7 (31.6)	25.9 (33.0)	22.9 (31.1)	25.3 (34.4)	20.0 (29.8)
<b>Post-initiation Month score<sup>a</sup></b>	22.7 (31.0)	24.0 (30.3)	24.1 (31.5)	19.0 (27.2)	23.2 (33.8)	21.1 (29.7)

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Absolute change<sup>b</sup></b>	1.5 (-5.4 to 8.4)	2.3 (-8.3 to 12.9)	-1.9 (-11.2 to 7.5)	-3.8 (-13.7 to 6.1)	-2.0 (-11.8 to 7.8)	1.1 (-11.8 to 14)
<b>% Change<sup>c</sup></b>	7.1%	10.7%	-7.1%	-16.7%	-8.0%	5.6%
<b>EORTC QLQ-GI.NET21: Sexual function</b>						
<b>Number of patients with paired scores</b>	20	19	18	17	17	15
<b>Baseline score<sup>a</sup></b>	33.3 (39.0)	40.4 (38.5)	37.0 (36.6)	37.3 (39.4)	37.3 (34.8)	35.6 (39.4)
<b>Post-initiation Month score<sup>a</sup></b>	36.7 (38.8)	38.6 (40.5)	42.6 (37.6)	43.1 (42.1)	43.1 (42.1)	37.8 (41.5)
<b>Absolute change<sup>b</sup></b>	3.3 (-7.9 to 14.5)	-1.8 (-11.7 to 8.2)	5.6 (-6.2 to 17.3)	5.9 (-5 to 16.8)	5.9 (-8 to 19.7)	2.2 (-6.2 to 10.7)
<b>% Change<sup>c</sup></b>	10.0%	-4.3%	15.0%	15.8%	15.8%	6.2%
<b>EORTC QLQ-GI.NET21: Treatment related symptoms scale<sup>d</sup></b>						
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>Number of patients</b>	41	33	32	33	30	24

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
Mean score <sup>d</sup>	23.3 (18.5 to 28.1)	20.7 (15.0 to 26.4)	22.0 (16.8 to 27.3)	15.3 (9.7 to 20.9)	18.9 (13.4 to 24.4)	14.1 (9.3 to 18.9)

**Table S8. EQ-ED-5L scores during the first 6 months of treatment with everolimus.** Data presented as: <sup>a</sup>mean (Standard deviation); <sup>b</sup>mean change from baseline (95% confidence intervals); <sup>c</sup>% change in mean from baseline.

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>EQ-5D composite health index (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression)</b>						
Number of patients with paired scores	43	43	36	36	32	30
Baseline score <sup>a</sup>	0.724 (0.201)	0.727 (0.169)	0.720 (0.159)	0.705 (0.162)	0.711 (0.127)	0.701 (0.156)
Post-initiation score at Month <sup>a</sup>	0.682 (0.250)	0.694 (0.207)	0.670 (0.180)	0.698 (0.174)	0.715 (0.183)	0.725 (0.153)
Absolute change <sup>b</sup>	-0.042 (-0.098 to 0.014)	-0.032 (-0.092 to 0.028)	-0.050 (-0.106 to 0.006)	-0.007 (-0.063 to 0.049)	0.004 (-0.052 to 0.061)	0.024 (-0.029 to 0.077)

	Post-initiation visit					
	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6
<b>% Change<sup>c</sup></b>	-5.8%	-4.4%	-7.0%	-1.0%	0.6%	3.4%
<b>EQ-5D self-rated (global) health status</b>						
<b>Number of patients with paired scores</b>	43	43	36	36	32	30
<b>Baseline score<sup>a</sup></b>	67.6 (19.5)	67.7 (17.1)	66.8 (16.7)	66.1 (17.1)	65.6 (16.4)	68.3 (15.2)
<b>Post-initiation Month score<sup>a</sup></b>	65.3 (23.0)	66.8 (19.0)	63.2 (17.3)	68.4 (16.5)	66.6 (17.8)	67.9 (17.5)
<b>Absolute change<sup>b</sup></b>	-2.4 (-8.1 to 3.4)	-0.8 (-7.1 to 5.4)	-3.6 (-8.9 to 1.7)	2.4 (-2.6 to 7.4)	1.0 (-4.6 to 6.6)	-0.4 (-7.1 to 6.3)
<b>% Change<sup>c</sup></b>	-3.5%	-1.2%	-5.4%	3.6%	1.5%	-0.6%